Betty Y.S. Kim, MD, Ph.D., FRCSC

AIMBE College of Fellows Class of 2023
For outstanding contributions to biomedical nanotechnology, especially to the development of nano-enabled immunotherapies for cancer.

Engineered Peptides Stimulate Antitumor Immune Responses in Mice

Via Genetic Engineering & Biotechnology News | April 22, 2024

Researchers have designed a new method for developing immunotherapy drugs using engineered peptides to elicit a natural immune response inside the body. More specifically, they showed, in antigen presenting cells, that “the hydrophobicity, electrostatic charge, and secondary conformation of helical polypeptides can be optimized to stimulate innate immune pathways via endoplasmic reticulum stress.”

In preclinical models of locally advanced and metastatic breast cancer, this method improved tumor control and prolonged survival, both as a monotherapy and in combination with immune checkpoint inhibitors… Continue reading.


Immunotherapy Response in Glioblastoma Induced by mRNA Delivered by Extracellular Vesicles

Via Inside Precision Medicine | October 20, 2023

Investigators at the University of Texas MD Anderson Cancer Center has developed a potentially groundbreaking method for enhancing immunotherapy responses in glioblastoma by using extracellular vesicles loaded with messenger RNA (mRNA). This new approach, detailed in Nature Communications, has solved some of the hurdles faced by mRNA-based therapy approaches for cancer and could lead to wider use of these therapies across a range of hard-to-treat tumor types.

The new approach for mRNA delivery builds on research from a team at MD Anderson led by Betty Kim, MD, PhD, and Wen Jiang, MD, PhD, who developed a novel method earlier this year of loading mRNA into extracellular vesicles and demonstrates the anti-tumor potential of this method of therapeutic delivery. Researchers have known for some time the therapeutic potential of mRNA to fight both infectious diseases and cancer. But methods to deliver it accurately to where it is needed has been a challenge, with various other potential delivery method studied previously including via lipid polymeric nanoparticles… Continue reading.


Research identifies new potential hurdle for nano-based therapies

Via MD Anderson Cancer Center | September 18, 2023

Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective in younger patients, highlighting the need for further investigation into the impact of aging on the body’s ability to respond to treatment.

The researchers found age-related differences are due to how effectively the liver filters the bloodstream. Younger livers are more efficient at this process, which helps limit toxins in the blood but also filters out beneficial treatments, potentially rendering them ineffective… Continue reading.


Betty Kim Elected to the 2023 Class of the AIMBE College of Fellows

Via AIMBE | March 27, 2023

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Betty Y.S. Kim, MD, Ph.D., FRCSC, Professor at University of Texas MD Anderson Cancer Center to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering or developing/implementing innovative approaches to bioengineering education… Continue reading.


Scientists develop novel mRNA delivery method using extracellular vesicles

Via MD Anderson Cancer Center | January 12, 2023

A team of researchers led by The University of Texas MD Anderson Cancer Center has developed a novel delivery system for messenger RNA (mRNA) using extracellular vesicles (EVs). The new technique has the potential to overcome many of the delivery hurdles faced by other promising mRNA therapies.

In the study, published today in Nature Biomedical Engineering, the researchers use EV-encapsulated mRNA to initiate and sustain collagen production for several months in the cells of photoaged skin in laboratory models. It is the first therapy to demonstrate this ability and represents a proof-of-concept for deploying the EV mRNA therapy… Continue reading.